E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
Fresenius Kabi holds the exclusive rights to commercialize Dr. Reddy’s Rituximab Biosimilar in the United States.
imphoenix82
Johnson & Johnson’s MONARCH Platform helps improve early lung cancer detection by enabling physicians to access and biopsy suspicious lung nodules that are difficult to reach with conventional bronchoscopy.
imphoenix82
The first edition of Pharmapack Asia is expected to attract more than 2,500 attendees, 120 exhibitors and visitors from over 40 countries
imphoenix82
The launch of Biocon’s Yesafili expands the availability of biosimilar aflibercept 2 mg for patients with age-related macular degeneration and other serious eye conditions in the US.
imphoenix82
AbbVie has received approval from the European Commission (EC) for RINVOQ (upadacitinib; 15 mg and 30 mg, once daily) to treat adults and adolescents aged 12 years and older with severe alopecia areata (AA). Alopecia areata is an autoimmune disorder that causes unpredictable hair loss, ranging from small bald patches on the scalp to complete […]
imphoenix82
Firefly Bio’s Firelink DAC platform will help advance Johnson & Johnson’s strategy to develop targeted therapies for some of the most prevalent and difficult-to-treat solid tumours.
imphoenix82
Chicago-based biopharmaceutical company Meitheal holds exclusive US commercialization rights for Garzulys through its exclusive license agreement with Emerge, the BLA holder.
imphoenix82
Teleflex has received Biologics License Application (BLA) approval for EZPLAZ Freeze Dried Plasma (FDP) from the USFDA.
imphoenix82
Johnson & Johnson’s RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) is currently approved in more than 40 countries, including the US, Europe and Japan, for the subcutaneous treatment of non-small cell lung cancer.
imphoenix82
The framework builds on WHO’s Greener pharmaceuticals’ regulatory highway call to action, launched in 2024.
imphoenix82HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.
